Ka la 26 Pherekhong 2025, Setsi sa Tlhahlobo ea Meriana (CDE) sa Tsamaiso ea Lihlahisoa tsa Bongaka ea Naha ea Chaena se phatlalalitse hore ente ea LM-108 e reretsoe ho kenyelletsoa kalafong ea katleho bakeng sa lihlahala tse tiileng tse tsoetseng pele tse nang le ho se tsitse ha microsatellite (MSI-H) kapa liphoso tsa tokiso e sa tsamaellaneng (dMMR) tse tsoetseng pele kamora kalafo ka li-immune checkpoint inhibitors (ICI).
LM-108 ke antibody e ncha e ntlafalitsoeng ke Fc, e loantšang CCR8 monoclonal e fokotsang Tregs e kenang ka har'a hlahala ka mokhoa o ikhethileng.
Mabapi le CCR8:
CCR8 (chemokine receptor 8) ke setho sa lelapa le lenyenyane la chemokine receptor tlas'a lelapa la G protein-coupled receptor (GPCR). Lithuto tse fetileng li senotse hore tlhahiso ea CCR8 e tlase liseleng tsa mali tse ka ntle le liseleng tse tloaelehileng, empa e eketsoa haholo-holo ho Tregs tse kenang ka har'a hlahala mefuteng e mengata ea kankere ho kenyeletsoa kankere ea matsoele, kankere ea mala a maholo le kankere ea matšoafo. Li-antibodies tsa Anit-CCR8 li ka thusa ka mokhoa o ikhethileng ho fokotsa Tregs tse kenang ka har'a hlahala, ka hona li ntlafatsa karabelo ea 'mele ea ho itšireletsa mafung khahlanong le hlahala le ho thibela kholo ea hlahala.
ASeboka sa Selemo le Selemo sa ASCO sa 2024，tlaleha tlhahlobo e kopaneng ea liphetho tse tsoang lithutong tsa mekhahlelo e 3 ea 1/2 (NCT05199753; NCT05255484; NCT05518045) ho lekola katleho le polokeho ea LM-108 hammoho le phekolo ea anti-PD-1 ho bakuli ba nang le kankere ea mala.
Mekhoa: Bakuli ba tšoanelehang ba nang le kankere ea mala ba phekoloang ka LM-108 hammoho le antibody ea anti-PD-1 ba kenyelelitsoe tlhahlobong. Bakuli ba ile ba fuoa LM-108 ka methapo maemong a tekanyo ea 3 mg/kg Q2W, 6 mg/kg Q3W, kapa 10 mg/kg Q3W hammoho le antibody ea anti-PD-1 (pembrolizumab ea methapong 200 mg Q3W kapa 400 mg Q6W kapa toripalimab 240 mg Q3W). Ntlha ea mantlha ea qetello e ne e le ORR e lekiloeng ke mofuputsi ho latela RECIST v1.1. Lintlha tsa bobeli tsa qetello li ne li kenyelletsa polokeho, liphetho tse ling tsa katleho, le tlhahlobo ea li-biomarker. Letsatsi la ho qetela la data bakeng sa tlhahlobo e kopantsoeng e ne e le la 25 Tšitoe 2023.
Liphetho: Bakuli ba mashome a mane a metso e robeli ba nang le kankere ea mala (lilemo tse mahareng: lilemo tse 60.5; banna: 72.9%) ba tsoang Chaena, USA le Australia ba ile ba phekoloa ka tekanyo e kaholimo ho 1 ea LM-108 hammoho le pembrolizumab kapa toripalimab. Bakuli ba bangata (n = 47, 97.9%) ba ne ba fumane bonyane kalafo e le 'ngoe ea pele ea ho loantša mofetše, 'me ba 43 (89.6%) ba ne ba fumane phekolo ea pele ea anti-PD-1. Liketsahalo tse mpe tse amanang le kalafo (TRAEs) li etsahetse ho bakuli ba 39 (81.3%), moo liketsahalo tse tloaelehileng haholo (≥15%) e neng e le alanine transaminase e eketsehileng (25.0%), aspartate transaminase e eketsehile (22.9%), lisele tse tšoeu tsa mali li fokotsehile (22.9%), khaello ea mali (16.7%). Kereiti ya ≥ 3 TRAEs di etsahetse ho bakudi ba 18 (37.5%), diketsahalo tse tlwaelehileng haholo (≥ 4%) e ne e le kgaello ya madi (8.3%), ho eketseha ha lipase (4.2%), ho ruruha ha letlalo (4.2%), le palo ya di-lymphocyte e fokotsehile (4.2%). Har'a bakudi ba 36 ba neng ba lekolwa ka katleho ho pholletsa le mefuta yohle ya kalafo, ORR e ne e le 36.1% (95% CI 20.8%–53.8%) mme DCR e ne e le 72.2% (95% CI 54.8%–85.8%). PFS e mahareng e ne e le dikgwedi tse 6.53 (95% CI 2.96–NA). Har'a bakudi ba 11 bao lefu la bona le neng le tswetse pele kalafong ya pele, ORR e ne e le 63.6% (95% CI 30.8%–89.1%) mme DCR e ne e le 81.8% (95% CI 48.2%–97.7%). Ho bakuli ba 11 ba ileng ba tsoela pele kalafong ea pele, ba 8 ba ne ba e-na le ponahalo e phahameng ea CCR8. Har'a bakuli bana ba 8, ORR e ne e le 87.5% 'me DCR e ne e le 100%, 'me ho ile ha bonoa CR e le 1, PR e 6, le SD e le 1.
Liqeto: LM-108 hammoho le antibody ea anti-PD-1 e bontšitse ts'ebetso e tšepisang ea ho loantša hlahala ho bakuli ba nang le kankere ea mala e neng e hanyetsana le phekolo ea anti-PD-1. Kalafo e kopaneng e ile ea mamelloa hantle. Liphetho tsena li tšehetsa tlhahlobo e eketsehileng ea LM-108 ho kankere ea mala e nang le CCR8.
Hona jwale, ho ntse ho na le diteko tse ngata tsa bongaka tsa mahlale a matjha a ho lwantsha kankere Chaena a batlang bakudi. Dipuisano mabapi le meriana le mahlale a matjha, o ka ikopanya le Lefapha la Matjhaba la Sepetlele sa Oncology sa Beijing Region South.
Nomoro ea mohala: 4008803716
Email：myimmnet@163.com
Litšupiso
1.https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d
2.https://www.lanovamedicines.com/en
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2504
Nako ea poso: Hlakola-06-2025